Search

The degradation of Reactive Yellow 18 (RY-18), induced by gamma radiation in aqueous medium, was carried out as a function of gamma radiation dose (5–20 kGy) and concentration of hydrogen peroxide, the initial dye concentration and pH of the solution were optimized for the maximum degradation efficiency. Gamma radiations alone and in combination with H2O2 were used to degrade the RY-18. A degradation rate of 99% was achieved using an absorbed dose of 20 kGy, 0.6 mL H2O2 in acidic pH. Variations in the functional groups of untreated and treated RY-18 were determined by FTIR analysis. The LCMS technique was used to determine the intermediates formed during the degradation process. The cytotoxicity and mutagenicity of RY-18 were studied by hemolytic and Ames tests, respectively. There were significant reductions in cytotoxicity and mutagenicity in response to gamma radiation treatment. Cytotoxicity was reduced from 15.1% to 7.6% after treatment with a 20 kGy absorbed dose of gamma radiations with 0.6 mL H2O2. Mutagenicity was reduced by 81.3% and 82.3% against the bacterial strains TA98 and TA100 after treatment with a 20 kGy absorbed dose with 0.6 mL H2O2. The advanced oxidation process efficiency was evaluated using the byproduct formations, which were low-molecular-weight organic acid units, which through further oxidation were converted into carbon dioxide and water end products. Based on RY-18 degradation, cytotoxicity and mutagenicity reduction, the gamma radiation in combination with H2O2 has potential for the removal of dye from the effluents. [ABSTRACT FROM AUTHOR]

This review highlights the underexplored potential and promises of marine bioactive peptides (MBPs) with unique structural, physicochemical, and biological activities to fight against the current and future human pathologies. A particular focus is given to the marine environment as a significant source to obtain or extract high-value MBPs from touched/untouched sources. For instance, marine microorganisms, including microalgae, bacteria, fungi, and marine polysaccharides, are considered prolific sources of amino acids at large, and peptides/polypeptides in particular, with fundamental structural sequence and functional entities of a carboxyl group, amine, hydrogen, and a variety of R groups. Thus, MBPs with tunable features, both structural and functional entities, along with bioactive traits of clinical and therapeutic value, are of ultimate interest to reinforce biomedical settings in the 21st century. On the other front, as the largest biome globally, the marine biome is the so-called "epitome of untouched or underexploited natural resources" and a considerable source with significant potentialities. Therefore, considering their biological and biomedical importance, researchers around the globe are redirecting and/or regaining their interests in valorizing the marine biome-based MBPs. This review focuses on the widespread bioactivities of MBPs, FDA-approved MBPs in the market, sustainable development goals (SDGs), and legislation to valorize marine biome to underlying the impact role of bioactive elements with the related pathways. Finally, a detailed overview of current challenges, conclusions, and future perspectives is also given to satisfy the stimulating demands of the pharmaceutical sector of the modern world. [ABSTRACT FROM AUTHOR]